CN101766708B - Quality control method of Chinese herbal preparation for rheumatism treatment - Google Patents
Quality control method of Chinese herbal preparation for rheumatism treatment Download PDFInfo
- Publication number
- CN101766708B CN101766708B CN2009102266507A CN200910226650A CN101766708B CN 101766708 B CN101766708 B CN 101766708B CN 2009102266507 A CN2009102266507 A CN 2009102266507A CN 200910226650 A CN200910226650 A CN 200910226650A CN 101766708 B CN101766708 B CN 101766708B
- Authority
- CN
- China
- Prior art keywords
- solution
- methyl alcohol
- water
- reference substance
- bath
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000003908 quality control method Methods 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 23
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 3
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 3
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 3
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 3
- 239000004863 Frankincense Substances 0.000 claims abstract description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- 238000012360 testing method Methods 0.000 claims description 28
- 239000013558 reference substance Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 241001465251 Ephedra sinica Species 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 4
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 241000173529 Aconitum napellus Species 0.000 claims description 2
- 241000601164 Clematis orientalis Species 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims description 2
- 229940023019 aconite Drugs 0.000 claims description 2
- 235000005412 red sage Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000004069 differentiation Effects 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 241001083548 Anemone Species 0.000 abstract 1
- 241000903946 Clematidis Species 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 17
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a quality control method of Chinese herbal preparation, which is a quality control method of collateral-activating and pain-relieving capsule. The quality control method of the invention is to perform differentiation or content determination to one or more ingredients of extractum acanthopanacis senticosi, radix clematidis, radix angelicae sinensis, radix aconiti preparata, radix aconiti kusnezoffii preparata, radde anemone rhizome, radix salviae miltiorrhizae, stir-fried frankincense, stir-fried myrrh and ephedra herb so as to achieve the purpose of quality control of the product (see drawings appended to the abstract). The invention has the advantages of effectively ensuring the drug efficacy and stability of the resulting collateral-activating and pain-relieving capsule through the differentiation or content determination to a plurality of ingredients in the prescription,, thus further protecting the administration safety of the patients.
Description
Technical field
The present invention relates to a kind of method of quality control of Chinese medicine preparation, relate in particular to a kind of method of quality control of Chinese medicine preparation of rheumatism.
Background skill scape
Rheumatism is a kind of systemic disease, and full name is " rheumatism ", is a kind of common disease frequently-occurring disease.It is of a great variety; Comprise kind surplus rheumatoid arthritis, lupus erythematosus, dermatomyositis, sclerderm, ankylosing spondylitis, rheumatic fever, infectional arthritis, the soft tissue rheumatism etc. 100; Wherein occurred frequently with several kinds of diseases such as ankylosing spondylitis, rheumatoid arthritis, Osteoarthritis especially; And prognosis is relatively poor, and disability rate is than higher.The cause of disease of these diseases is different, and common performance is but arranged: limbs, joint, myalgia, or with swelling, inconvenient activity.Patient's pain is unbearably, and is handicapped, and be difficult to cure, and many patients lack rheumatismal understanding, do not know how to prevent and go to a doctor, to such an extent as to the state of an illness finally is difficult to reverse by light to heavy, and serious deformity even the life-threatening of causing.
So, very multiple type rheumatism class medicine has appearred on the market, and the validity of rheumatism class medicine and the stable content that has become day by day for everybody paid close attention to.
The active pain preparation that disappears is the Chinese medicine patent medicine that is used to treat illnesss such as wind-cold-dampness arthralgia, channels and collaterals obturation, arthralgia and myalgia and numb limb.List marketing at present active pain relieving tablet and two kinds of formulations of active pain-eliminating capsule are arranged.Wherein the standard of tablet institute foundation is numbered: WS3-B-0355-90, in this standard, what apply to is existing current techique, can reach the purpose of the most basic control drug quality.
But along with the continuous progress of pharmaceutical technology, reach the purpose of safer medication, must constantly improve the drug standards.Especially contain Chinese ephedra in the preparation raw material medicine of the present invention; Ephedrine hydrochloride in the Chinese ephedra is in a single day excessive; Will cause anxious, have a sleepless night, tremble, the serious side effects of cardiovascular and cerebrovascular such as palpitaition, headache, dizzy, nauseating, vomiting, poor appetite, elevation of blood pressure, renal shutdown, perspiration and fash and nervous system aspect; Entail dangers to is to medication person's life security, and the strictness that therefore its content in medicine also received State Food and Drug Administration limits.
Just be based on this, the present invention puts forth effort on the better drug quality of the active pain preparation that disappears of control of research.
Summary of the invention
The purpose of this invention is to provide a kind of method of quality control of treating the Chinese medicine preparation of rheumatism; It is the method for quality control by the prepared active pain-eliminating capsule of bulk drug Extractum Acanthopanacis Senticosi, the root of Chinese clematis, Radix Angelicae Sinensis, aconiti preparata,radix, wild aconite root, Radde Anemone Rhizome, the red sage root, frankincense, myrrh, Chinese ephedra; Come better to guarantee the stability of medicine with this; Quality controllability makes medication safer, effective.
The objective of the invention is to realize, comprise that Determination of Ephedrine Hydrochloride is measured in following discriminating and/or microscopical identification and/or the Chinese ephedra through following technical scheme:
The discriminating of wilsonii
These article of getting content 0.35-1g, porphyrize adds methyl alcohol 10ml-30ml, sonicated 10-30 minute, filters; Filtrating is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 0.5-1.5ml, and as need testing solution, other gets wilsonii control medicinal material 2.5-7.5g, adds 75% ethanol 25-75ml; Reflux 0.5-1.5 hour, put coldly, filter, filtrating is put evaporate to dryness in the water-bath, and residue adds water 5-15ml makes dissolving; Add chloroform and extract 1-3 time, each 5-15ml, combined chloroform liquid is put evaporate to dryness in the water-bath; Residue adds methyl alcohol 0.5-1.5ml makes dissolving, as control medicinal material solution, gets the isofraxidin reference substance again, adds methyl alcohol and processes the solution that every 0.5-1.5ml contains 0.5-1.5mg; As reference substance solution, according to the thin-layered chromatography test, draw above-mentioned three kinds of each 5-15ul of solution, put respectively on same silica gel g thin-layer plate; The chloroform-methanol that with the ratio is 9-29: 0.5-1.5 is a developping agent, launches, and takes out, and dries; Put under the 365nm ultraviolet lamp and inspect, in the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show the spot of same color; With the position of reference substance chromatogram on, show the spot of same color;
Microscopical identification
These article of getting content, put microscopically and observe: lithocyte is colourless, with apparent brown, type square, rectangle like, similar round, class prismatic or the strip that metaderm links, diameter 20-133um; Long 50-190um, wall are thick slightly, and wall thickness person laminated striation is obvious, and the many bunchys of fiber are faint yellow; Be elongated strip, terminal short point, the visible short branch that has, edge out-of-flatness, diameter 22-56um; Wall thickness 4-8um, tool edge line cell rufous, polygon, wall is thin, the phloem parenchyma cell spindle; Wall is slightly thick, and atomic thin oblique cross lamination is arranged, and the epidermal cell fragment is faint yellow, and the cell rectangle includes small calcium oxalate crystal.
Assay
Assay is according to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: use octadecylsilane chemically bonded silica to be filling agent; Acetonitrile-0.1% phosphoric acid solution that with the ratio is 3.5-10: 46-140 is a moving phase: the detection wavelength is 207nm, and number of theoretical plate calculates by the ephedrine hydrochloride peak should be not less than 3000;
It is an amount of that the preparation precision of reference substance solution takes by weighing the ephedrine hydrochloride reference substance, adds methyl alcohol and process and contain 20ug solution among every 1ml, promptly get,
These article content 1.7-5.2g is got in the preparation of need testing solution, stable precision, and porphyrize is got about 0.5-1.5g, and accurate the title, decide; Put conical flask, add 30-90% ethanol 25-75ml, ultrasonic 15-45 minute, put coldly, filter; With a small amount of 30-90% ethanol gradation washing filter residue and filter, merging filtrate and washing lotion are put and are steamed in the water-bath to there not being the alcohol flavor, add water 15-45ml, are transferred in the separating funnel; Shake up, add strong ammonia solution and regulate pH value, add diethyl ether again and extract 2-7 time, merge ether solution, put low temperature evaporate to dryness in the water-bath to 10-11; Residue adds dissolve with methanol and is transferred in the 12-37ml measuring bottle, adds methyl alcohol to scale, shakes up, and promptly gets
Accurate respectively reference substance solution and each 2.5-7.5ul of need testing solution of drawing of determination method injects liquid chromatograph, measures, promptly get,
Determination of Ephedrine Hydrochloride experiment in the starting material Chinese ephedra medicinal material of active pain-eliminating capsule, concrete test method and result are following:
1, instrument and reagent
Instrument: Autech high performance liquid chromatograph; C
18(Hypersil ODS
2250 * 4.6mm, 5u) chromatographic column, Cschrom data processing software.Reagent: acetonitrile is a chromatorgaphy reagent, and water is redistilled water, and it is pure that other reagent is analysis.
Reference substance:, supply assay to use for Nat'l Pharmaceutical & Biological Products Control Institute provides.
2, chromatographic condition
Moving phase: acetonitrile-0.1% phosphoric acid solution (7: 93)
Detect wavelength: 207nm; Flow velocity: 1.0nm/min.
Under above-mentioned selected condition, to measure through the HPLC method, other component chromatographic peak can reach baseline separation in ephedrine hydrochloride peak and the sample, and adjacent chromatographic peak degree of separation with other is greater than 1.5; Press the ephedrine hydrochloride peak and calculate, number of theoretical plate is more than 3000; In the negative solution chromatogram with ephedrine hydrochloride chromatographic peak relevant position on do not have chromatographic peak, explain that feminine gender is noiseless, reference substance, test sample, negative sample chromatogram are seen Fig. 1,2,3 respectively.
3, need testing solution preparation
It is tolerant to get these article 10 intragranulars, stable precision, and porphyrize is got about 1g, stable precision; Put conical flask, add 60% ethanol 50ml, ultrasonic 30 minutes, put coldly, filter; With a small amount of 60% ethanol gradation washing filter residue and filter, merge filter night and washing lotion, put and steam in the water-bath to there not being the alcohol flavor, add water 30ml, be transferred in the separating funnel; Shake up, add strong ammonia solution and transfer to pH value, add diethyl ether again and extract (25,20,20,10,10ml) 5 times, merge ether solution, put low temperature evaporate to dryness in the water-bath to 10-11; Residue adds dissolve with methanol and is transferred in the 25ml measuring bottle, adds methyl alcohol to scale, shakes up, and promptly gets.
4, the preparation of negative solution
Get other recipe quantity medicinal materials except that Chinese ephedra, be prepared into the negative sample 1g that lacks Chinese ephedra, process the negative solution that lacks Chinese ephedra by the need testing solution preparation method by preparation technology.
5, the preparation of reference substance solution
Precision takes by weighing ephedrine hydrochloride reference substance 5.21mg, puts in the 50ml measuring bottle, adds dissolve with methanol and is diluted to scale; Shake up (0.1042mg/ml), the accurate 3ml that draws puts in the 20ml measuring bottle; Add methyl alcohol and be diluted to scale, shake up, promptly get (hydrochloric ephedrine 0.01536mg among every 1ml).
6, linear relationship is investigated
Accurate absorption concentration is ephedrine hydrochloride reference substance solution 1,3,5,7, the 9ul sample introduction of 0.01536mg/ml; Measure its peak area integrated value; With concentration is horizontal ordinate, and the peak area integrated value is an ordinate, the drawing standard curve; Its regression equation is: A=54564576.1C+172066.7, r=0.9996. result show that ephedrine hydrochloride has good linear relationship in the 0.02048-0.18432ug scope.Data are seen table 1, and typical curve is seen Fig. 4.
Table 1 linear relationship is investigated table as a result
| Concentration (ug) | 0.01536 | 0.04608 | 0.0768 | 0.10752 | 0.13824 |
| Peak area | 934622 | 2723959 | 4480878 | 5991898 | 7681770 |
7, precision test
The same need testing solution 5ul of accurate absorption repeats sample introduction 5 times, measures its peak area integrated value, and its result sees table 2.
Table 2 Precision test result table
The result shows: this law precision is good.
8, stability test
Get same need testing solution respectively at 0,2,4,6,8 hour sample introduction, measure its peak area integrated value, the result sees table 3.
Table 3 stability test is table as a result
| Time (hour) | ?0 | 2 | 4 | 6 | 8 |
| Peak area value | ?4409154 | 4393798 | 4392978 | 4373959 | 4385798 |
The result shows that need testing solution peak area value in 12 hours is basicly stable.
9, reappearance test
Get same lot number sample by above-mentioned condition, measure 5 times (n=2), the result sees table 4.
Table 4 reproducible test results table
The result shows that average content is 0.1372mg/ grain (0.3916mg/g), this law favorable reproducibility.
10, recovery test
Precision takes by weighing known content and is the about 0.5g of 0.3916mg/g sample; Respectively accurate ephedrine hydrochloride reference substance solution (0.0942mg/ml) 2ml that adds, i.e. 0.1884mg is from " adding 60% ethanolic solution 50ml "; Measure content by the method under the above-mentioned assay item, the result sees table 5.
Table 5 determination of recovery rates is table as a result
The result shows that this method average recovery is good.
11, sample determination method and result
By the above-mentioned content assaying method working sample of drafting, the result sees table 6.
Table 6 sample size is measured table as a result
| Lot number | 20030518 | 20030520 | 20030522 | 20041020 | 20041022 |
| Content (mg/ grain) | 0.09 | 0.09 | 0.09 | 0.12 | 0.12 |
| Lot number | 20041024 | 20050812 | 20050814 | 20050816 | |
| Content (mg/ grain) | 0.12 | 0.14 | 0.14 | 0.14 |
Above-mentioned sample size is pressed 70% conversion of average content 0.117mg/ grain in 0.09-0.14mg/ grain scope, Determination of Ephedrine Hydrochloride must not be less than 0.08mg in every of these article of regulation.
Specific embodiment
The discriminating of specific embodiment one wilsonii
These article of getting content 0.7g, porphyrize adds methyl alcohol 20ml, and sonicated 20 minutes filters; Filtrating is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 1ml, and as need testing solution, other gets wilsonii control medicinal material 5g, adds 75% ethanol 50ml; Reflux 1 hour is put coldly, filters, and filtrating is put evaporate to dryness in the water-bath, and residue adds water 10ml makes dissolving; Add chloroform and extract 2 times, each 10ml, combined chloroform liquid is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 1ml makes dissolving; As control medicinal material solution, get the isofraxidin reference substance again, add methyl alcohol and process the solution that every 1ml contains 1mg, as reference substance solution, according to the thin-layered chromatography test; Drawing above-mentioned three kinds of each 10ul of solution, put respectively on same silica gel g thin-layer plate, is that 19: 1 chloroform-methanol is a developping agent with ratio, launches, and takes out; Dry, put under the 365nm ultraviolet lamp and inspect, in the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show the spot of same color; With the position of reference substance chromatogram on, show the spot of same color.
Specific embodiment two microscopical identification
Get content of the present invention, put microscopically and observe: lithocyte is colourless, with apparent brown, type square, rectangle like, similar round, class prismatic or the strip that metaderm links, diameter 60um; Long 100um, wall are thick slightly, and wall thickness person laminated striation is obvious, and the many bunchys of fiber are faint yellow; Be elongated strip, terminal short point, the visible short branch that has, edge out-of-flatness, diameter 40um; Wall thickness 6um, tool edge line cell rufous, polygon, wall is thin, the phloem parenchyma cell spindle; Wall is slightly thick, and atomic thin oblique cross lamination is arranged, and the epidermal cell fragment is faint yellow, and the cell rectangle includes small calcium oxalate crystal.
Specific embodiment three assays
Assay is according to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: use octadecylsilane chemically bonded silica to be filling agent; With ratio is that 7: 93 acetonitrile-0.1% phosphoric acid solution is a moving phase: the detection wavelength is 207nm; Number of theoretical plate calculates by the ephedrine hydrochloride peak and should be not less than 3000, and it is an amount of that the preparation precision of reference substance solution takes by weighing the ephedrine hydrochloride reference substance, adds methyl alcohol and processes and contain 20ug solution among every 1ml; Promptly get
Content 3.5g of the present invention is got in the preparation of need testing solution, stable precision, and porphyrize is got about 1g, and accurate the title, decide; Put conical flask, add 60% ethanol 50ml, ultrasonic 30 minutes, put coldly, filter; With a small amount of 60% ethanol gradation washing filter residue and filter, merging filtrate and washing lotion are put and are steamed in the water-bath to there not being the alcohol flavor, add water 30ml, are transferred in the separating funnel; Shake up, add strong ammonia solution and regulate pH value, add diethyl ether again and extract 5 times, merge ether solution, put low temperature evaporate to dryness in the water-bath to 10-11; Residue adds dissolve with methanol and is transferred in the 25ml measuring bottle, adds methyl alcohol to scale, shakes up, and promptly gets
Accurate respectively reference substance solution and each 5ul of need testing solution of drawing of determination method injects liquid chromatograph, measures, and promptly gets.
Description of drawings:
1, Fig. 1 is an ephedrine hydrochloride reference substance chromatogram;
2, Fig. 2 is active pain-eliminating capsule test sample chromatogram;
3, Fig. 3 is active pain-eliminating capsule negative sample chromatogram;
4, Fig. 4 is the ephedrine hydrochloride linear relationship chart.
Claims (2)
1. detection method of treating the Chinese medicine preparation of rheumatism; This Chinese medicine preparation is by bulk drug Extractum Acanthopanacis Senticosi, the root of Chinese clematis, Radix Angelicae Sinensis, aconiti preparata,radix, wild aconite root, Radde Anemone Rhizome, the red sage root, frankincense, myrrh, the prepared active pain-eliminating capsule of Chinese ephedra, it is characterized in that the differential method of wilsonii in the active pain-eliminating capsule may further comprise the steps:
Get active pain-eliminating capsule content 0.35-1g, porphyrize adds methyl alcohol 10ml-30ml, sonicated 10-30 minute, filters; Filtrating is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 0.5-1.5ml, and as need testing solution, other gets perverse slender acanthopanax control medicinal material 2.5-7.5g, adds 75% ethanol 25-75ml; Reflux 0.5-1.5 hour, put coldly, filter, filtrating is put evaporate to dryness in the water-bath, and residue adds water 5-15ml makes dissolving; Add chloroform and extract 1-3 time, each 5-15ml, combined chloroform liquid is put evaporate to dryness in the water-bath; Residue adds methyl alcohol 0.5-1.5ml makes dissolving, as control medicinal material solution, gets the isofraxidin reference substance again, adds methyl alcohol and makes the solution that every 0.5-1.5ml contains 0.5-1.5mg; As reference substance solution, according to the thin-layered chromatography test, draw above-mentioned three kinds of each 5-15ul of solution, put respectively on same silica gel g thin-layer plate; The chloroform-methanol that with the ratio is 9-29: 0.5-1.5 is a solvent, launches, and takes out, and dries; Put under the 365nm ultraviolet lamp and inspect, in the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show the spot of same color; With the position of reference substance chromatogram on, show the spot of same color.
2. the differential method of wilsonii may further comprise the steps in the detection method as claimed in claim 1, wherein active pain-eliminating capsule:
Get active pain-eliminating capsule content 0.7g, porphyrize adds methyl alcohol 20ml, and sonicated 20 minutes filters; Filtrating is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 1ml, and as need testing solution, other gets wilsonii control medicinal material 5g, adds 75% ethanol 50ml; Reflux 1 hour is put coldly, filters, and filtrating is put evaporate to dryness in the water-bath, and residue adds water 10ml makes dissolving; Add chloroform and extract 2 times, each 10ml, combined chloroform liquid is put evaporate to dryness in the water-bath, and residue adds methyl alcohol 1ml makes dissolving; As control medicinal material solution, get the isofraxidin reference substance again, add methyl alcohol and make the solution that every 1ml contains 1mg, as reference substance solution, according to the thin-layered chromatography test; Drawing above-mentioned three kinds of each 10ul of solution, put respectively on same silica gel g thin-layer plate, is that 19: 1 chloroform-methanol is a solvent with ratio, launches, and takes out; Dry, put under the 365nm ultraviolet lamp and inspect, in the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show the spot of same color; With the position of reference substance chromatogram on, show the spot of same color.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102266507A CN101766708B (en) | 2009-12-16 | 2009-12-16 | Quality control method of Chinese herbal preparation for rheumatism treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102266507A CN101766708B (en) | 2009-12-16 | 2009-12-16 | Quality control method of Chinese herbal preparation for rheumatism treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103027394A Division CN102426206A (en) | 2009-12-16 | 2009-12-16 | Quality control method of traditional Chinese medicine preparation for treating rheumatism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101766708A CN101766708A (en) | 2010-07-07 |
| CN101766708B true CN101766708B (en) | 2012-07-04 |
Family
ID=42499909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102266507A Active CN101766708B (en) | 2009-12-16 | 2009-12-16 | Quality control method of Chinese herbal preparation for rheumatism treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766708B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108548885A (en) * | 2018-06-21 | 2018-09-18 | 江苏康缘药业股份有限公司 | The method that two-dimensional liquid chromatography detects compound Nanxing pain paste |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547818A (en) * | 2013-10-25 | 2015-04-29 | 王波 | Production technology of Hantongle Yunji and quality control method thereof |
| CN103720799B (en) * | 2013-11-26 | 2016-05-18 | 山东大学齐鲁医院(青岛) | A kind of preparation method of active pain relieving tablet and application |
| CN106214770B (en) * | 2016-09-18 | 2020-04-10 | 天地恒一制药股份有限公司 | Application of collateral activating and pain relieving capsule in preparation of medicine for treating diabetic peripheral neuropathy |
-
2009
- 2009-12-16 CN CN2009102266507A patent/CN101766708B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 中华人民共和国药典委员会.活络消痛片.《中药成分制剂第2册》.1990,z2－185. * |
| 李瑞莲,雷玉萍.活络消痛胶囊质量标准的研究.《中国药师》.2006,第9卷(第5期),439-440. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108548885A (en) * | 2018-06-21 | 2018-09-18 | 江苏康缘药业股份有限公司 | The method that two-dimensional liquid chromatography detects compound Nanxing pain paste |
| CN108548885B (en) * | 2018-06-21 | 2021-04-30 | 江苏康缘药业股份有限公司 | Method for detecting compound arisaema analgesic plaster by two-dimensional liquid chromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101766708A (en) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Improved quality control method for Danshen products—consideration of both hydrophilic and lipophilic active components | |
| Daodee et al. | Effects of the ethanol extract of Dipterocarpus alatus leaf on the unpredictable chronic mild stress-induced depression in ICR mice and its possible mechanism of action | |
| Diawara et al. | Validation, transfer and measurement uncertainty estimation of an HPLC–UV method for the quantification of artemisinin in hydro alcoholic extracts of Artemisia annua L. | |
| CN101766708B (en) | Quality control method of Chinese herbal preparation for rheumatism treatment | |
| CN102426205B (en) | Detection method of thrombus sumalin capsules | |
| CN102552496A (en) | Quality detection method of compound stomachache treating capsules | |
| Wang et al. | Comparative analysis of four terpenoids in root and cortex of Tripterygium wilfordii Radix by different drying methods | |
| CN102397517A (en) | Quality control method of traditional Tibetan medicinal lipid lowering preparation | |
| CN102552616A (en) | Detection method for tablets capable of relaxing muscles and stimulating blood circulation | |
| CN101700262A (en) | Quality control method of andrographis paniculata dropping pills | |
| CN102707006B (en) | Quality detection method of cudrania tricuspidata formula granules | |
| CN102426206A (en) | Quality control method of traditional Chinese medicine preparation for treating rheumatism | |
| CN101361781A (en) | Fingerprint checking method of gadol injection | |
| CN101401880B (en) | Quality control method for Ditong rhinitis drop and mist | |
| CN102507844B (en) | Testing method for Xueshuan xinmaining tablet | |
| CN101181343A (en) | Mass control method of rhinitis tablet of climbing groundsel and spikemoss | |
| CN101721530A (en) | Method for controlling quality of Jinji preparation | |
| CN100410662C (en) | Tripterygium glycosides and their preparation wilforlide A content determining method | |
| Yang et al. | Simultaneous quantification of five major active components in capsules of the traditional Chinese medicine ‘Shu-Jin-Zhi-Tong’by high performance liquid chromatography | |
| CN105004833A (en) | Detection method for traditional Chinese medicine preparation for treating acute gouty arthritis and gout | |
| Gowda | High-performance liquid chromatographic determination of colchicine in pharmaceutical formulations and biological fluids | |
| CN101785818A (en) | Content determination method for active ingredients of wound curative capsule | |
| CN101377482B (en) | Quality control method of Fengdima eye drops | |
| CN101357204A (en) | Quality control method of traditional Chinese medicine preparation for treating pain | |
| CN105467051A (en) | Dachuanxiong tablet whole-time multi-wavelength fusion fingerprint quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100707 Assignee: HUNAN DEKANG PHARMACEUTICAL CO., LTD. Assignor: Deng Lili Contract record no.: 2014430000131 Denomination of invention: Quality control method of Chinese herbal preparation for rheumatism treatment Granted publication date: 20120704 License type: Exclusive License Record date: 20140715 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: HUNAN DEKANG PHARMACEUTICAL CO., LTD. Assignor: Deng Lili Contract record no.: 2014430000131 Date of cancellation: 20150610 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100707 Assignee: HuNan TianDiHengYi Pharmacy Co., Ltd Assignor: Deng Lili Contract record no.: 2015430000076 Denomination of invention: Quality control method of Chinese herbal preparation for rheumatism treatment Granted publication date: 20120704 License type: Exclusive License Record date: 20150618 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151012 Address after: 410331 Hunan province Changsha city Changsha national biological industry base Kang Road No. 109 Patentee after: HuNan TianDiHengYi Pharmacy Co., Ltd Address before: Shaoshan City, Hunan province 410007 Changsha Road No. 39 Victoria Star City Taurus room 1202 Patentee before: Deng Lili |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Quality control method of Chinese herbal preparation for rheumatism treatment Effective date of registration: 20161202 Granted publication date: 20120704 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: HuNan TianDiHengYi Pharmacy Co., Ltd Registration number: 2016430000051 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20171130 Granted publication date: 20120704 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: HuNan TianDiHengYi Pharmacy Co., Ltd Registration number: 2016430000051 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Quality control method of Chinese herbal preparation for rheumatism treatment Effective date of registration: 20171206 Granted publication date: 20120704 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: HuNan TianDiHengYi Pharmacy Co., Ltd Registration number: 2017430000099 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 410331 No. 109 Kangtian Road, Changsha National Biological Industrial Base, Changsha City, Hunan Province Patentee after: Tiandi Hengyi Pharmaceutical Co., Ltd. Address before: 410331 No. 109 Kangtian Road, Changsha National Biological Industrial Base, Changsha City, Hunan Province Patentee before: HuNan TianDiHengYi Pharmacy Co., Ltd |
|
| CP01 | Change in the name or title of a patent holder | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190809 Granted publication date: 20120704 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: HuNan TianDiHengYi Pharmacy Co., Ltd Registration number: 2017430000099 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Quality control method of Chinese herbal preparation for rheumatism treatment Effective date of registration: 20190816 Granted publication date: 20120704 Pledgee: Bank of Changsha Limited by Share Ltd Liuyang branch Pledgor: Tiandi Hengyi Pharmaceutical Co., Ltd. Registration number: Y2019430000002 |